Market Cap 51.68M
Revenue (ttm) 2.82M
Net Income (ttm) -127.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,521.28%
Debt to Equity Ratio 0.23
Volume 811,500
Avg Vol 844,148
Day's Range N/A - N/A
Shares Out 56.75M
Stochastic %K 82%
Beta 1.03
Analysts Strong Sell
Price Target $6.00

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 399 9500
Address:
830 Winter Street, Waltham, United States
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 24 at 8:09 PM
$TCRX where to now? steady climb? or flatten out under a buck
0 · Reply
SocioCobb
SocioCobb Dec. 24 at 2:14 AM
$TCRX Wooly bully...
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 23 at 11:45 PM
$TCRX lynx bought large on the open market last few trading days watch out
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 20 at 3:01 PM
$TCRX holiday sale on this name looks like funds clearing inventory end of qtr i'm buying the discount
0 · Reply
soll
soll Dec. 19 at 2:59 PM
$TCRX Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines https://share.google/Mqf1iuJJzXGBMAU5f
0 · Reply
GeorgeJonesFan_In_Boston
GeorgeJonesFan_In_Boston Dec. 17 at 8:53 PM
$TCRX I guess TScan won’t be getting the Top Place To Work award for the 4th consecutive year this year with laying off 30% of employees in November. I live about 25 minutes away from them, I should visit them.
1 · Reply
Deliver1
Deliver1 Dec. 17 at 8:14 PM
$TCRX Level II ASK = stacked as far as the eye can see. Level II BID = low support. This is going down .90 or lower Merry Xmas TCRX shareholders, enjoy that stuffed crow or pigeon with a reverse split notification on a Christmas tree!
1 · Reply
Deliver1
Deliver1 Dec. 17 at 7:49 PM
$TCRX Question: Why is TCRX stock looking like garbage?
0 · Reply
GeorgeJonesFan_In_Boston
GeorgeJonesFan_In_Boston Dec. 16 at 5:21 PM
$TCRX and the bleeding continues. What a disappointment this stock has been.
1 · Reply
PaulLaurent
PaulLaurent Dec. 14 at 7:10 PM
🧭 Weekly Swing Recap $MIST – +29% from the entry zone — finished just shy of the second target; partials on strength worked. $ANIX – +44% from the entry zone — second target exceeded; great follow-through. $TCRX – +14% from the entry zone — second target hit; trail stops protected gains. $UPXI – Breakeven initially, then -11% from the entry if held — stop discipline mattered. $PSTV – +22% from the entry zone — first target hit; tidy execution. Tone: Even in chop, the plan delivers—enter clean, scale at targets, and respect stops.
1 · Reply
Latest News on TCRX
TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 7, 2025, 11:31 AM EST - 10 months ago

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025


TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 19, 2024, 10:05 AM EDT - 1 year ago

TScan Therapeutics Announces Closing of Upsized Public Offering


SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 24 at 8:09 PM
$TCRX where to now? steady climb? or flatten out under a buck
0 · Reply
SocioCobb
SocioCobb Dec. 24 at 2:14 AM
$TCRX Wooly bully...
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 23 at 11:45 PM
$TCRX lynx bought large on the open market last few trading days watch out
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 20 at 3:01 PM
$TCRX holiday sale on this name looks like funds clearing inventory end of qtr i'm buying the discount
0 · Reply
soll
soll Dec. 19 at 2:59 PM
$TCRX Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines https://share.google/Mqf1iuJJzXGBMAU5f
0 · Reply
GeorgeJonesFan_In_Boston
GeorgeJonesFan_In_Boston Dec. 17 at 8:53 PM
$TCRX I guess TScan won’t be getting the Top Place To Work award for the 4th consecutive year this year with laying off 30% of employees in November. I live about 25 minutes away from them, I should visit them.
1 · Reply
Deliver1
Deliver1 Dec. 17 at 8:14 PM
$TCRX Level II ASK = stacked as far as the eye can see. Level II BID = low support. This is going down .90 or lower Merry Xmas TCRX shareholders, enjoy that stuffed crow or pigeon with a reverse split notification on a Christmas tree!
1 · Reply
Deliver1
Deliver1 Dec. 17 at 7:49 PM
$TCRX Question: Why is TCRX stock looking like garbage?
0 · Reply
GeorgeJonesFan_In_Boston
GeorgeJonesFan_In_Boston Dec. 16 at 5:21 PM
$TCRX and the bleeding continues. What a disappointment this stock has been.
1 · Reply
PaulLaurent
PaulLaurent Dec. 14 at 7:10 PM
🧭 Weekly Swing Recap $MIST – +29% from the entry zone — finished just shy of the second target; partials on strength worked. $ANIX – +44% from the entry zone — second target exceeded; great follow-through. $TCRX – +14% from the entry zone — second target hit; trail stops protected gains. $UPXI – Breakeven initially, then -11% from the entry if held — stop discipline mattered. $PSTV – +22% from the entry zone — first target hit; tidy execution. Tone: Even in chop, the plan delivers—enter clean, scale at targets, and respect stops.
1 · Reply
Deliver1
Deliver1 Dec. 11 at 7:17 PM
$TCRX Article of interest: Japanese Pharmas Looking Beyond Borders for M&A to US, EU: ( not sure how applicable here for TCRX - posting anyway) https://www.biospace.com/business/japanese-pharmas-looking-beyond-borders-for-m-a-to-us-eu EXCERPT1 "Those companies are getting more and more aggressive. Daichii has promised to beef up its immuno-oncology pipeline with outside assets while building out AstraZeneca-partnered Enhertu in a seemingly endless number of indications."
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Dec. 9 at 4:53 PM
$TCRX good recovery ... back to original alert price
0 · Reply
Deliver1
Deliver1 Dec. 8 at 8:44 PM
$TCRX TERN - ( Terns Pharmaceutical) having a great day on their trial presentation!! and it's for CML a less severe blood cancer https://finance.yahoo.com/news/terns-highlights-additional-positive-phase-194500720.html TCRX = dead in the water stock
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Dec. 8 at 7:22 PM
$TCRX $TCRX news is good. more catalysts ahead.
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 8 at 6:33 PM
$TCRX numbers looked decent someone didnt like em? or some bad news hidden somewhere?
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Dec. 8 at 4:07 PM
$TCRX news is good here... 100% vs 25%. IND News ahead Trading way below cash as well
0 · Reply
Drugtrade
Drugtrade Dec. 8 at 3:07 PM
$TCRX bought the dip.. very small pos so far likely adds in 70s.. swing trade up $1+
0 · Reply
glaucio76
glaucio76 Dec. 8 at 10:17 AM
$TCRX 0 reaction in pre market 🥴
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 7 at 11:08 PM
$TCRX TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition "3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control arm"
0 · Reply
Deliver1
Deliver1 Dec. 7 at 9:03 PM
$TCRX Anybody dialing into KOL tomorrow? Can somebody please ask about RMAT designation - if that is still in effect and how that could effect the parameters for the upcoming TSC-101 pivotal trial. ( i think that's a air question) May 29/24 presser on RMAT designation. https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-receives-fdas-regenerative-medicine-advanced Thanks in advance.
0 · Reply
Deliver1
Deliver1 Dec. 7 at 8:59 PM
$TCRX https://finance.yahoo.com/news/tscan-therapeutics-announces-positive-updated-223000522.html
0 · Reply
TA_Kongen
TA_Kongen Dec. 7 at 7:51 PM
$TCRX New data out. Some key points via the 8k + chatgpt + study design. Shows a ~50% reduction in relapse risk (HR ~0.46–0.50) with very clean safety. Strong mechanistic signals (MRD conversion to negative; improved donor chimerism). Not statistically significant yet because the trial is small (Phase 1, ~20 pts/arm). Competition? Mainly “transplant alone” (standard of care after RIC haplo-HCT). In some patients, post-transplant maintenance drugs (e.g., FLT3 inhibitors like sorafenib or gilteritinib). No direct cell-therapy competitors exist in this specific relapse-prevention niche. Efficacy compared to competitors? The effect size looks similar to best-in-class maintenance regimens (many also reduce relapse by ~40–60%). But those drugs have large, randomized, statistically significant data; TSC-101 does not yet. Safety is better than most drug maintenance options (lower toxicity, no GVHD penalty).
0 · Reply